Imatinib Completed Phase 2 Trials for Cancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer Treatment

CompletedTreatment2 IdentifierTitleDrugs
NCT00216112Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
NCT00510653Gleevec Study for Patients With Ovarian Cancer
NCT00039585Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor